MENU
KROS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Keros Therapeutics (KROS) Ownership - Who owns Keros Therapeutics?
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs... Show more
Profile
Industry
N/A
Address
1050 Waltham Street
Phone
+1 617 314-6297
Employees
136
Web
https://www.kerostx.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
613.7M
P/E Ratio
N/A
Total Cash
720.54M
Projected Growth
N/A
Total Debt
18.41M
Revenue
214.71M
Risk (Beta)
1.40
Dividend Yield
N/A
Total Cash/Share
17.74
Total Debt/Equity
N/A
Revenue/Share
5.54 USD as % of share price
Fundamentals
KROS
Capitalization
614M
P/E Ratio
N/A
Risk (Beta)
1.40
Dividend Yield
N/A
Total Cash
721M
Total Cash/Share
17.74
Total Debt
18.4M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
5.54%
Revenue
215M
ROE
N/A
Book Value
729M
P/B Ratio
0.84
Cash Flow
N/A
Earnings
-0.13
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
4K
Current Ratio
19.29
Current Revenue Per Employee
1295987.80
Dividends Per Share - Security
N/A
EBITDA
14.8M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
0.66
Shares Held By Institutions
995M
Shares Outstanding - Current
40.6M
Total Liabilities
55.7M
Total Volume MTD
N/A
Value
1
Gain YTD
-4.548
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a biopharmaceutical company, which focuses on treatments for rare muscle diseases
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
1050 Waltham Street
Phone
+1 617 314-6297
Employees
136
Web
https://www.kerostx.com